home
01

Elevar Therapeutics

Since its establishment in 2005, Elevar Therapeutics has developed new drugs for various types of cancer based on its long experience in the development of new anti-cancer drugs and has leapt forward as an anti-cancer drug company through the introduction of new drugs in the research or early clinical stages.

Business Area

Rivoceranib

Rivoceranib is a selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumor- mediated angiogenesis. Rivoceranib is a low-molecular inhibitor that is highly regarded as the best-in- class drug due to its high VEGRF-2 selectivity and fewer side effects.

Ongoing Project

- Development of Paclitaxel Micellar, a Cremophor-free formulation of paclitaxel, is underway for the ovarian cancer treatment.
- Increased convenience without prior treatment by applying patent-applied Micelle coating.
- An optimal mixture of Paclitaxel based on the form of additives developed to reduce side effects.

* It received a marketing authorization by the European Medicines Agency (EMA) under the name of medical product Apealea® (paclitaxel micellar) in 2018, and is currently being commercialized in Europe and in the Middle East and North Africa (MENA) region.

Company information
HQ
address

2825 E Cottonwood Pkwy Suite 180,Salt Lake City, UT 84121 U.S.A.

Tel

+1-801-303-7440


Fax

+1-801-303-7455

SFO Office
address

400 Oyster Point Blvd, Suite 214, South San Francisco, CA 94080 U.S.A.

Home

www.elevartherapeutics.com

E-mail

info@elevartherapeutics.com

HLB
GROUP
LIST
02

Immunomic
Therapeutics

Since its establishment in 2006, Immunomic Therapeutics, Inc. (ITI) has been a privately held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. In particular, “UNITE”, the next-generation vaccine platform, shows excellent scalability for various cancers and allergies based on its high technology.

Business Area

UNITE (the next-generation vaccine platform)

UNITE stands for 'Universal Intracellular Targeted Expression'. UNITE is a powerful next-generation immunotherapy platform technology that targets specific antigens to lysosomes to increase antigen presentation and enhance cytotoxic T cell function. This platform is a highly scalable platform that can be applied to cancer and allergies.

Glioblastoma Treatment

Glioblastoma has not been approved for new drugs in the past 20 years. ITI's glioblastoma drug substance has a five-year survival rate of about seven times higher than existing drugs, and the median overall survival rate (OS) is over 40 months.

Company information
Headquarters & Lab
address

15010 Broschart Road Suite 250 Rockville, MD 20850

Tel

+1-301-968-3501

Home

www.immunomix.com

E-mail

info@immunomix.com

03

HLB Life Science
Co., Ltd.

HLB Life Science leaps forward as a global pharmaceutical company based on the discovery of first-in-class / best-in-class innovative new drugs and a differentiated new drug development network based on unmet need analysis.

Business Area

Domestic Research of Rivoceranib

The bio business division of HLBLS is currently developing ‘Best-in-Class’ targeted-anticancer drug Rivoceranib (Apatinib) for marketing approval in Korea. HLBLS plans to maximize the versatility of Rivoceranib by expanding research in various cancer areas (stomach cancer, liver cancer, colon cancer etc.), non-cancer areas (age-related macular degeneration and dry eye disease) and animal cancers.

Seclidemstat: biomarker based solid tumor drug development

Seclidemstat normalizes tumor-related gene expressions that suppress proliferation and metastasis of cancer cells. It regulates lysine-specific histone demethylase 1A(LSD-1) that is over-activated in various tumor cells. It is a first-in-class epigenetic anticancer drug with a new promising MOA.

Company information
HQ
Address

8F, 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do, Republic of Korea

Tel

+82-2-2627-6748

Fax

+82-2-2627-6702

Seoul Office
Address

(06193) 420, Teheran-ro, Mayple Tower 15f, Gangnam-gu, Seoul, Republic of Korea

Tel

+82-2-2627-6700

Fax

+82-2-2627-6703

Home

www.hlb-ls.com

E-mail

hlbls@hlb-ls.com

04

HLB Pharma

Established in 1998, HLB Pharma has taken its first step forward to evolve into a company developing new drugs specialized for degenerative brain diseases. The company will make relentless efforts to develop new drugs under the goal to develop the company through curing and caring patients.

Business Area

ETC drugs

125 drugs including Roche Duo Tab, Radova Tab, Glitia soft cap, and Ctpezil Tab

OTC drugs

40 drugs including Pramax Cream/Suppositories

CMO

190 drugs including L-Carnitine, Aceclofenac

Health Functional Food

Preparing to launch four products

R&D

CTT-004 (C-Trelin OD Tablet)

Spinocerebellar degeneration is a rare disease in which the cells making up the cerebellum die due to unknown mechanisms. Ataxia is the main symptom caused by spinocerebellar degeneration. As there has been no therapeutic agent with efficacy and safety proven through large-scale clinical trials, HLB Pharma is currently carrying out clinical trial that aims to prove efficacy and safety at major domestic university hospitals, using the taltirelin hydrate.

SMEB® Technology

SMEB (Smart continuous Manufacturing system for Encapsulated Biodrug) technology is the continuous manufacturing technology for long-acting injectable formulations, which have an automatic systems for production and quality control. Currently, HLB Pharmaceutical is conducting research and development of anti-coagulants, dementia treatments, and Parkinson's treatments as well as peptide drugs, and is promoting open innovation with domestic and foreign companies.

Company Information
HQ
address

9F, MK Tower, 67, Jeongui-ro, Songpa-gu, Seoul

Tel

+82 2-411-1500

Fax

+82 2-411-1590

Factory / Lab
address

27, Gyeonggang-ro, Namyangju-si, Gyeonggi-do

Tel

+82 2-577-0001

Fax

+82 31-557-6622

Home

www.hlbpharma.co.kr

E-mail

sail@hlbpharma.co.kr

05

HLB Cell

Founded in 2009, HLB Cell has been focusing on specialized stem cell research, including bio-artificial liver, and biomedical engineering research, with the deepest understanding of "Cell," the fundamental unit of life phenomena, and suggests regenerative medical treatment for incurable diseases. It has differentiated pipelines such as bio-artificial liver, stem cell therapy, and surgical hemostatic agents.

Business Area

Bio Artificial Liver

LifeLiver™ is a cell therapy for prolonging the golden time of patients with acute liver failure waiting for liver transplantation.

Stem Cell Therapy

It is a stem cell therapeutic that can be applied to liver disease (urea dystrophy, nonalcoholic steatohepatitis, etc.) and soft tissue disease by applying mass culture technology to new stem cells derived from human body.

Biodegradable Medical Adhesive
· Sealant

It is a powder-type product that can be used during surgery as well as various external bleedings.

Company information
HQ & Lab
address

8F, 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do

Tel

+82-31-709-8578

Fax

+82-31-701-8579

Home

www.hlbcell.co.kr

E-mail

hlbcell@hlbcell.co.kr

05

Hwajin Medical
Co., Ltd.

Since its establishment in 1993, Hwajin Medical has grown into a manufacturer specializing in producing medical devices and currently taking up to 20-25% of the domestic syringe market. The main products are disposable syringes, disposable needles, and filter syringes.

Business Area
Disposable Syringe
Disposable Injection Needle
Membrane Filter Syringe
Certification Status
Delivery Performance
Company information
HQ
address

20, Seongsimwon-gil, Seongnam-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do

Tel

+82-41-554-6181

Fax

+82-41-554-7178

Home

www.hwajinmedical.com

E-mail

hwajin@hwajinmedical.com

07

Shinhwa Advance
Co., Ltd.

Since its establishment in 1991, Shinhwa Advance has been supplying its products to national/public hospitals as an online and offline specialty drug distribution company and is continuously seeking to expand its business opportunities.

Business Area

distribution and sale

Shinhwa Advance is carrying out business with leading pharmaceutical companies, and by establishing various pipelines such as general and professional medicines, they are planning to become a specialized distributor that could diversify profit structures.

Delivery Performance
해외 주요거래처
Company information
HQ
Address

150-858 191, Daebangcheon-ro, Yeongdeungpo-gu, Seoul (2nd floor of Shinhwa Building)

Tel

+82-2-834-7971

Fax

+82-2-834-7938

E-mail

shparm7@hanmail.net